久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Dynacure Receives Orphan Drug Designation for DYN101 americanpharmaceuticalreview
    August 12, 2019
    Dynacure announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2) for ...
  • Ionis-backed Dynacure bags €47M to start clinical trials fiercebiotech
    July 09, 2018
    Dynacure has raised €47 million ($55 million) to take an antisense oligonucleotide therapy into the clinic. The French biotech picked up the centronuclear myopathy (CNM) prospect from its cofounder, Ionis Pharmaceuticals.
PharmaSources Customer Service